Fig. 2
From: Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial
The primary efficacy measures at endpoint (ITT-LOCF analysis). a VADAS-cog mean change from baseline score in three groups. VADAS-cog Vascular Dementia Assessment Scale-Cognitive Subscale (VADAS-cog). p < 0.05 Tianzhi vs placebo in the mean change after 24 weeks’ treatment, p < 0.05 donepezil vs placebo in the mean change after 24 weeks’ treatment, p > 0.05 Tianzhi vs donepezil. ITT intent-to-treat, LOCF last observation carried forward, PPS per protocol set. b CIBIC-plus at endpoint (week 24) in three groups. CIBIC-plus Clinician Interview-Based Impression of Change scale Clinician’s Interview-Based Impression of Change–plus version. Overall treatment p < 0.01. p < 0.01 Tianzhi vs placebo, p < 0.01 donepezil vs placebo, p > 0.05 donepezil vs Tianzhi